Journals / Turkish archives of pediatrics (Online) / 2021 / Cilt: 56 - Sayı: 6

Long-Term Follow-Up of Patients with a Diagnosis of Posterior Reversible Encephalopathy Syndrome

Pages
569–575
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antiepileptic treatment can be stopped in the early period in patients with normal MRI and electroencephalogram by eliminating the factors that trigger the seizures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The essential characteristics of posterior reversible encephalopathy syndrome (PRES) are the presence of acute onset neurologic symptoms, focal vasogenic edema at neuroimaging, and reversible clinical and/or radiologic findings.
📊
Key Findings & Data:Results: Seventeen patients with PRES were evaluated (mean age at onset, 10.23 ± 4.65 years; range, 2-17 years; girls, 29.4% [n = 5]).
💡
Conclusion & Impact:Antiepileptic treatment can be stopped in the early period in patients with normal MRI and electroencephalogram by eliminating the factors that trigger the seizures.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: The essential characteristics of posterior reversible encephalopathy syndrome (PRES) are the presence of acute onset neurologic symptoms, focal vasogenic edema at neuroimaging, and reversible clinical and/or radiologic findings. This study aimed to evaluate the clinical findings, causes, radiologic findings, and prognoses of patients with PRES. Methods: Patients with PRES confirmed with clinical and radiologic findings by a pediatric neurologist were evaluated retrospectively. Results: Seventeen patients with PRES were evaluated (mean age at onset, 10.23 ± 4.65 years; range, 2-17 years; girls, 29.4% [n = 5]). The mean length of follow-up was 6 ± 2.3 years (range, 3.4-10 years). Mortality due to primary disease occurred in 4 patients (23.5%) during follow-up. PRES was derived from renal diseases in 10 patients (58.8%), hematologic diseases in 6 patients (35.3%), and liver disease in one patient (5.9%). Hypertension was present in 16 patients (94.1%) at onset of PRES (>99th percentile). Seizure, the most frequent initial symptom, was observed in 82.4% (n = 14). Blurred vision and headache were the initial symptoms in 3 patients (17.6%). Sequelae were observed at magnetic resonance imaging (MRI) in 6 patients. Development of epilepsy was determined as a sequela in 4 patients (23.5%) and mental motor retardation in 2 patients (11.8%). Conclusion: Epilepsy is uncommon in patients who have recovered from PRES. The presence of gliosis on MRI and interictal epileptic discharges on electroencephalograms are major risk factors for the development of epilepsy. Antiepileptic treatment can be stopped in the early period in patients with normal MRI and electroencephalogram by eliminating the factors that trigger the seizures.

🔖

Cite This Article

CANPOLAT, M., OZCORA, G. D. K., PORAZOĞLU, H., PER, H., ÇOŞKUN, A., GÜMÜŞ, H., ARSLAN, D., ÜNAL, E., KARAKÜKCÜ, M., PATIROĞLU, T., KUMANDAŞ, S. (2021). Long-Term Follow-Up of Patients with a Diagnosis of Posterior Reversible Encephalopathy Syndrome. Turkish archives of pediatrics (Online), Cilt: 56 - Sayı: 6, 569–575. https://ajindex.com/articles/403409

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996
  2. 334(8):494-500. [CrossRef] 2. Lamy C, Oppenheim C, Mas JL. Posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2014
  3. [CrossRef] 3. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017
  4. 264(8):1608-1616. [CrossRef] 4. Thavamani A, Umapathi KK, Puliyel M, et al. Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States. Pediatr Neurol. 2020
  5. [CrossRef] 5. Gümüş H, Per H, Kumandaş S, Yikilmaz A. Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci. 2010
  6. 31(2):125-131. [CrossRef] 6. Emeksiz S, Kutlu NO, Çaksen H, et al. Posterior reversible encephalopathy syndrome in children: a case series. Turk Pediatr Ars. 2016
  7. 51(4):217-220. [CrossRef] 7. Yamamoto H, Natsume J, Kidokoro H, et al. Clinical and neuroimaging findings in children with posterior reversible encephalopathy syndrome. Eur J Paediatr Neurol. 2015
  8. 19(6):672-678. [CrossRef] 8. Pilato F, Calandrelli R, Distefano M, et al. Acute radiological pattern and outcome in posterior reversible encephalopathy syndrome patients. Clin Neurol Neurosurg. 2019
  9. 105459. [CrossRef] 9. Tek ŞÇ, Uyar AŞ, Çakıcı Z, et al. Posterior reversible encephalopathy syndrome: two case reports. tybd. 2019
  10. 17(1):44-48. [CrossRef] 10. Akın F, Kılıçaslan C, Solak ES, et al. Posterior reversible encephalopathy syndrome in children: report of three cases. Childs Nerv Syst. 2014
  11. 30(3):535-540. [CrossRef] 11. Freedman D, Koram A, Gillson N, Aylward SC. Pediatric posterior reversible encephalopathy syndrome (PRES) with spinal cord involvement due to pheochromocytoma. Pediatr Neurol. 2017
  12. [CrossRef] 12. Gungor S, Kilic B, Tabel Y, et al. Clinical and imaging findings in childhood posterior reversible encephalopathy syndrome. Iran J Child Neurol. 2018
  13. 12(1):16-25. 13. Singh RR, Ozyilmaz N, Waller S, et al. A study on clinical and radiological features and outcome in patients with posterior reversible encephalopathy syndrome (PRES). Eur J Pediatr. 2014
  14. 173(9):1225- 1231. [CrossRef] 14. Hartmann H. Posterior reversible encephalopathy: an epileptic syndrome? Neuropediatrics. 2017
  15. 48(2):64-65. [CrossRef] 15. Endo A, Fuchigami T, Hasegawa M, et al. Posterior reversible encephalopathy syndrome in childhood: report of f